์ฝ๋ฅดํฐ์ ์์ธํ ์ดํธ
**์ฝ๋ฅดํฐ์ ์์ธํ ์ดํธ**๋ **๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋**์ **๋ฏธ๋ค๋๋ก์ฝ๋ฅดํฐ์ฝ์ด๋** ํจ๊ณผ๋ฅผ ๋ชจ๋ ๊ฐ๋ ๊ฒฝ๊ตฌ์ฉ ์ฝ๋ฅดํฐ์ฝ์คํ ๋ก์ด๋์ ๋๋ค. ์ฃผ์ ์์ ํน์ง: * **์ ๊ตฌ์ฝ๋ฌผ ํน์ฑ**: ์์ฒด ๋ด์์ ๊ฐ์ ํตํด ์ฝ๋ฅดํฐ์(ํ๋๋ก์ฝ๋ฅดํฐ์)๋ก ์ ํ๋๊ธฐ ์ ๊น์ง๋ ์๋ฌผํ์ ์ผ๋ก ๋นํ์ฑ ์ํ์ ๋๋ค. * **์๋์จ๋ณ ๊ด๋ฆฌ**: ๋ฐ๋ ค๊ฒฌ์ ๋ถ์ ํผ์ง๊ธฐ๋ฅ์ ํ์ฆ(์๋์จ๋ณ) ๊ฒฝ๊ตฌ ์น๋ฃ ์ ํ๋ ๋๋์๋ก ์ ์ ์ฌ์ ๋์์ผ๋ก ์ฌ์ฉ๋ ์ ์์ต๋๋ค. ๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋์ ๋ฏธ๋ค๋๋ก์ฝ๋ฅดํฐ์ฝ์ด๋ ํ์ฑ์ ๋ชจ๋ ์ ๊ณตํ๋ฏ๋ก, 1์ฐจ ๋ฏธ๋ค๋๋ก์ฝ๋ฅดํฐ์ฝ์ด๋ ์ฝ๋ฌผ(์: ํ๋ฃจ๋๋ก์ฝ๋ฅดํฐ์)์ ์๊ตฌ ์ฉ๋์ ์ค์ฌ ์ ๋ฐ์ ์ธ ์น๋ฃ ๋น์ฉ์ ๋ฎ์ถ ์ ์์ต๋๋ค. * **๋ ผ๋**: ์์ํ์์๋ ํํ๊ฒ ์ฌ์ฉ๋์ง ์์ผ๋ฉฐ, ์ฆ๊ฐ๋ ๋ฏธ๋ค๋๋ก์ฝ๋ฅดํฐ์ฝ์ด๋ ํ์ฑ์ด ํ์ค ํ๋ ๋๋์๋ก ์๋ฒ์ ๋นํด ์์์ ์ผ๋ก ์ ์๋ฏธํ ์ด์ ์ ์ ๊ณตํ๋์ง์ ๋ํด์๋ ๋ด๋ถ๋นํ์๋ค ์ฌ์ด์์ ๋ ผ๋์ด ์์ต๋๋ค. * **์์ ์ฑ ํ๋กํ์ผ**: ์๋์จ๋ณ์ ์๋ฆฌ์ ๋ณด์ถฉ ์ฉ๋์ผ๋ก ์ฌ์ฉํ ๊ฒฝ์ฐ ์ผ๋ฐ์ ์ผ๋ก ๋ด์ฝ์ฑ์ด ๋งค์ฐ ์ข์ต๋๋ค. ์ด์๋ฆฌ์ ์ฉ๋์ผ๋ก ์ฌ์ฉ ์ ์ ํ์ ์ธ ์ฝ๋ฅดํฐ์ฝ์คํ ๋ก์ด๋ ๋ถ์์ฉ(์: ๋ค์/๋ค๋จ/๋ค์, ํ๋ก์, ๋ฉด์ญ ์ต์ )์ ์ ๋ฐํ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Cortisone acetate is a prodrug. Upon oral absorption, it undergoes first-pass hepatic metabolism where the enzyme **11ฮฒ-hydroxysteroid dehydrogenase type 1 (11ฮฒ-HSD1)** converts it into the active hormone, **cortisol**. * **Glucocorticoid Action**: Cortisol diffuses across cell membranes and binds to cytosolic **glucocorticoid receptors (GR)** โ the receptor-ligand complex translocates to the nucleus โ binds to glucocorticoid response elements (GREs) on DNA โ alters gene transcription (transactivation of anti-inflammatory proteins and transrepression of pro-inflammatory cytokines). * **Mineralocorticoid Action**: Cortisol also binds to **mineralocorticoid receptors (MR)** in the distal renal tubules โ promotes sodium retention and potassium excretion, which is critical for patients with hypoadrenocorticism.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Long-term treatment of hypoadrenocorticism (changeover period) ยท 0.5-1 mg/kg PO q12-24h ยท PO ยท q12-24h ยท Initial stabilization ยท Used initially with a semi-selective mineralocorticoid (fludrocortisone).
- Long-term treatment of hypoadrenocorticism (maintenance) ยท 0.5 mg/kg PO q12-24h ยท PO ยท q12-24h ยท Long-term ยท Provides adequate additional glucocorticoid supplementation once stable.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypersensitivity to cortisone acetate
- Systemic fungal infections (general corticosteroid contraindication)
์ด์๋ฐ์
- Vomiting
- Inappetence
- Diarrhea
- Hypersensitivity reactions (rare)
- Polyuria/Polydipsia/Polyphagia (at supra-physiologic doses)
- Panting (at supra-physiologic doses)
- Immunosuppression (at supra-physiologic doses)
์ฝ๋ฌผ ์ํธ์์ฉ
- Amphotericin B ยท Concomitant use may cause hypokalemia; risk of CHF and cardiac enlargement reported in humans.
- Aspirin ยท Glucocorticoids may reduce salicylate blood levels and increase risk for GI ulceration/bleeding.
- Diuretics, Potassium-Depleting (e.g., furosemide, thiazides) ยท Concomitant administration may cause hypokalemia.
- Estrogens ยท May potentiate the effects of hydrocortisone/glucocorticoids.
- Insulin and Antidiabetic Agents ยท Insulin requirements may increase due to glucocorticoid-induced insulin resistance.
- Mitotane ยท May alter steroid metabolism; higher doses of steroids may be needed to treat mitotane-induced adrenal insufficiency.
- NSAIDs ยท Increased risk of gastrointestinal ulceration and bleeding.
- Vaccines (Live attenuated) ยท Virus replication may be augmented if given at immunosuppressive doses; diminished immune response to killed vaccines/toxoids.
- Warfarin ยท May affect INR values; requires monitoring.
๋ชจ๋ํฐ๋ง
- Weight, appetite, signs of edema
- Serum and/or urine electrolytes (Na+, K+)
- Total plasma proteins, albumin
- Blood glucose
- Growth and development in young animals
- ACTH stimulation test (Note: Cortisone cross-reacts with cortisol assays; must test before administration)
๊ณผ์ฉ๋
Acute ingestion is rarely a clinical problem, and severe clinical effects are unlikely with a single acute overdose. However, neuropsychiatric effects can occur. Cardiac arrhythmias and anaphylaxis are theoretically possible but very rare. Treatment is generally supportive.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.